A Phase III, Open -Label, Randomised, Controlled, Multi-centre Study to assess the Efficacy and Safety of Olaparib Monotherapy versus Physician’s choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with germline BRCA1/2 Mutations